An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 8:15 a.m. ET. A live audio webcast will be available on the company's website, with a replay accessible one hour post-event for 21 days. Seres focuses on microbiome therapeutics, showcasing its SER-109 program, which received Breakthrough Therapy and Orphan Drug designations from the FDA for treating recurrent C. difficile infections. Additionally, SER-301 and SER-155 are under evaluation in clinical studies for ulcerative colitis and gastrointestinal infections.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:15 a.m. ET.
A live audio webcast of the presentation will be available under the “Investors and News” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 21 days.
About Seres Therapeutics Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C.difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit www.serestherapeutics.com.
When will Seres Therapeutics present at the J.P. Morgan Healthcare Conference?
Seres Therapeutics will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 8:15 a.m. ET.
How can I listen to the Seres Therapeutics presentation?
A live audio webcast of the presentation will be available on the Seres Therapeutics website under the 'Investors and News' section.
What is the focus of Seres Therapeutics' SER-109 program?
The SER-109 program focuses on treating recurrent C. difficile infections and has received Breakthrough Therapy and Orphan Drug designations from the FDA.
What are the other clinical programs Seres Therapeutics is working on?
Seres Therapeutics is evaluating SER-301 for ulcerative colitis and SER-155 for gastrointestinal infections in Phase 1b studies.
